Verve Therapeutics, Inc. (VERV): Price and Financial Metrics


Verve Therapeutics, Inc. (VERV): $22.57

-0.72 (-3.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VERV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VERV Stock Price Chart Interactive Chart >

Price chart for VERV

VERV Price/Volume Stats

Current price $22.57 52-week high $43.00
Prev. close $23.29 52-week low $10.70
Day low $22.14 Volume 433,500
Day high $22.99 Avg. volume 598,479
50-day MA $21.28 Dividend yield N/A
200-day MA $24.68 Market Cap 1.39B

Verve Therapeutics, Inc. (VERV) Company Bio


Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease.


VERV Latest News Stream


Event/Time News Detail
Loading, please wait...

VERV Latest Social Stream


Loading social stream, please wait...

View Full VERV Social Stream

Latest VERV News From Around the Web

Below are the latest news stories about VERVE THERAPEUTICS INC that investors may wish to consider to help them evaluate VERV as an investment opportunity.

2 High-Risk, High-Reward Stock Bets Cathie Wood Is Taking Into 2023

The tech-heavy Nasdaq represents a collection of more risky stocks than the other major indexes and that is reflected by a poorer performance in bear markets and a better display during bull runs. But the risks associated with the Nasdaq are mere child play compared to edgier funds such as Cathie Wood’s Ark Innovation ETF. Now that really hit the skids during last year’s bear, but the fund is also up 37% year-to-date, putting the Nasdaq's 15% gain in the shade. In fact, throwing more shade the N

Yahoo | February 6, 2023

Being Cautious On Regulatory/Commercial Path, This Analyst Initiates Coverage On Verve Therapeutics

Cantor Fitzgerald initiated coverage on Verve Therapeutics Inc (NASDAQ: VERV) with a Neutral rating and a price target of $21. The analyst says Verve is a true pioneer in gene editing, planning to develop base editing medicines for HeFH and the prevention of ASCVD, both prevalent diseases with large potential markets. However, the analyst sees heightened regulatory and commercial risk compared to other gene-editing/ genetic medicines companies focused on rare diseases. The analyst believes it wo

Yahoo | February 1, 2023

7 CRISPR Stocks With the Best Long-Term Potential 

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Alex Sirois on InvestorPlace | January 31, 2023

7 CRISPR Stocks With the Best Long-Term Potential

CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks

Yahoo | January 31, 2023

Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 4:30 p.m. PT in San Francisco. A live webcast will be available in the investor section of the company's websit

Yahoo | January 3, 2023

Read More 'VERV' Stories Here

VERV Price Returns

1-mo 10.42%
3-mo 14.51%
6-mo -33.21%
1-year -18.81%
3-year N/A
5-year N/A
YTD 16.64%
2022 -47.52%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7231 seconds.